Skip to main content
Top
Published in: Comparative Hepatology 1/2004

Open Access 01-01-2004 | Research

The establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patterns

Authors: Sacha Y Boomkens, Bart Spee, Jooske IJzer, Ronald Kisjes, Herman F Egberink, Ted SGAM van den Ingh, Jan Rothuizen, Louis C Penning

Published in: Comparative Hepatology | Issue 1/2004

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most worldwide frequent primary carcinomas resulting in the death of many cirrhotic patients. Unfortunately, the molecular mechanisms of this cancer are not well understood; therefore, we need a good model system to study HCC. The dog is recognized as a promising model for human medical research, namely compared with rodents. The objective of this study was to establish and characterize a spontaneous canine tumor cell line as a potential model for studies on HCC.

Results

Histomorphological, biochemical, molecular biological and quantitative assays were performed to characterize the canine HCC cell line that originated from a dog with a spontaneous liver tumor. Morphological investigations provided strong evidence for the hepatocytic and neoplastic nature of the cell line, while biochemical assays showed that they produced liver-specific enzymes. PCR analysis confirmed expression of ceruloplasmin, alpha-fetoprotein and serum albumin. Quantitative RT-PCR showed that the canine HCC cell line resembles human HCC based on the measurements of expression profiles of genes involved in cell proliferation and apoptosis.

Conclusions

We have developed a novel, spontaneous tumor liver cell line of canine origin that has many characteristics of human HCC. Therefore, the canine HCC cell line might be an excellent model for comparative studies on the molecular pathogenesis of HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37: S4-S66. 10.1016/S0959-8049(01)00267-2.CrossRefPubMed Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37: S4-S66. 10.1016/S0959-8049(01)00267-2.CrossRefPubMed
2.
go back to reference Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87: 159-170. 10.1016/S0092-8674(00)81333-1.CrossRefPubMed Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87: 159-170. 10.1016/S0092-8674(00)81333-1.CrossRefPubMed
4.
go back to reference Savolainen P, Zhang Y, Luo J, Lundeberg J, Leitner T: Genetic evidence for an East Asian origin of domestic dogs. Science. 2002, 298: 1610-1613. 10.1126/science.1073906.CrossRefPubMed Savolainen P, Zhang Y, Luo J, Lundeberg J, Leitner T: Genetic evidence for an East Asian origin of domestic dogs. Science. 2002, 298: 1610-1613. 10.1126/science.1073906.CrossRefPubMed
5.
go back to reference Kimura Y, Leung PS, Kenny TP, Van De Water J, Nishioka M, Giraud AS, Neuberger J, Benson G, Kaul R, Ansari AA, Coppel RL, Gershwin ME: Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology. 2002, 36: 1227-1235. 10.1053/jhep.2002.36157.CrossRefPubMed Kimura Y, Leung PS, Kenny TP, Van De Water J, Nishioka M, Giraud AS, Neuberger J, Benson G, Kaul R, Ansari AA, Coppel RL, Gershwin ME: Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology. 2002, 36: 1227-1235. 10.1053/jhep.2002.36157.CrossRefPubMed
6.
go back to reference Klocke R, Gomez-Lechon MJ, Ehrhardt A, Mendoza-Figueroa T, Donato MT, Lopez-Revilla R, Castell JV, Paul D: Establishment and characterization of immortal hepatocytes derived from various transgenic mouse lines. Biochem Biophys Res Commun. 2002, 294: 864-871. 10.1016/S0006-291X(02)00579-X.CrossRefPubMed Klocke R, Gomez-Lechon MJ, Ehrhardt A, Mendoza-Figueroa T, Donato MT, Lopez-Revilla R, Castell JV, Paul D: Establishment and characterization of immortal hepatocytes derived from various transgenic mouse lines. Biochem Biophys Res Commun. 2002, 294: 864-871. 10.1016/S0006-291X(02)00579-X.CrossRefPubMed
7.
go back to reference Weber A: Immortalization of hepatic progenitor cells. Pathol Biol (Paris). 2004, 52: 93-96.CrossRef Weber A: Immortalization of hepatic progenitor cells. Pathol Biol (Paris). 2004, 52: 93-96.CrossRef
8.
go back to reference Ogawa K, Nakanishi H, Takeshita F, Futakuchi M, Asamoto M, Imaida K, Tatematsu M, Shirai T: Establishment of rat hepatocellular carcinoma cell lines with differing metastatic potential in nude mice. Int J Cancer. 2001, 91: 797-802.CrossRefPubMed Ogawa K, Nakanishi H, Takeshita F, Futakuchi M, Asamoto M, Imaida K, Tatematsu M, Shirai T: Establishment of rat hepatocellular carcinoma cell lines with differing metastatic potential in nude mice. Int J Cancer. 2001, 91: 797-802.CrossRefPubMed
9.
go back to reference Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, Gaudino G: SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA. 2001, 98: 12032-12037. 10.1073/pnas.211026798.PubMedCentralCrossRefPubMed Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, Gaudino G: SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA. 2001, 98: 12032-12037. 10.1073/pnas.211026798.PubMedCentralCrossRefPubMed
10.
go back to reference Minervi MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA: Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997, 10: 686-692. Minervi MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA: Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997, 10: 686-692.
11.
go back to reference Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T: Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Path. 2001, 25: 1388-1396. 10.1097/00000478-200111000-00006.CrossRefPubMed Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T: Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Path. 2001, 25: 1388-1396. 10.1097/00000478-200111000-00006.CrossRefPubMed
12.
go back to reference Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999, 59: 307-310.PubMed Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999, 59: 307-310.PubMed
13.
go back to reference Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B: Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 2001, 44: 32-43. 10.1002/prot.1069.CrossRefPubMed Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B: Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 2001, 44: 32-43. 10.1002/prot.1069.CrossRefPubMed
14.
go back to reference Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E: Expression of hepatocyte growth factor and its receptor c-MET proto-oncogene in hepatocellular carcinoma. Hepatology. 1997, 25: 862-866. 10.1002/hep.510250413.CrossRefPubMed Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E: Expression of hepatocyte growth factor and its receptor c-MET proto-oncogene in hepatocellular carcinoma. Hepatology. 1997, 25: 862-866. 10.1002/hep.510250413.CrossRefPubMed
15.
go back to reference Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003, 3: 347-361. 10.1016/S1535-6108(03)00085-0.CrossRefPubMed Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003, 3: 347-361. 10.1016/S1535-6108(03)00085-0.CrossRefPubMed
16.
go back to reference Tannapfel A, Wittekind C: Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch. 2002, 440: 345-352. 10.1007/s00428-002-0617-x.CrossRefPubMed Tannapfel A, Wittekind C: Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch. 2002, 440: 345-352. 10.1007/s00428-002-0617-x.CrossRefPubMed
17.
go back to reference Scheid MP, Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546: 108-112. 10.1016/S0014-5793(03)00562-3.CrossRefPubMed Scheid MP, Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546: 108-112. 10.1016/S0014-5793(03)00562-3.CrossRefPubMed
18.
go back to reference Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T: Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004, 113: 1774-1783. 10.1172/JCI200420513.PubMedCentralCrossRefPubMed Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T: Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004, 113: 1774-1783. 10.1172/JCI200420513.PubMedCentralCrossRefPubMed
19.
go back to reference Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J, Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 2003, 201: 238-249. 10.1002/path.1420.CrossRefPubMed Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J, Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 2003, 201: 238-249. 10.1002/path.1420.CrossRefPubMed
20.
go back to reference Schipper RG, Penning LC, Verhofstad AA: Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors?. Semin Cancer Biol. 2000, 10: 55-68. 10.1006/scbi.2000.0308.CrossRefPubMed Schipper RG, Penning LC, Verhofstad AA: Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors?. Semin Cancer Biol. 2000, 10: 55-68. 10.1006/scbi.2000.0308.CrossRefPubMed
Metadata
Title
The establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patterns
Authors
Sacha Y Boomkens
Bart Spee
Jooske IJzer
Ronald Kisjes
Herman F Egberink
Ted SGAM van den Ingh
Jan Rothuizen
Louis C Penning
Publication date
01-01-2004
Publisher
BioMed Central
Published in
Comparative Hepatology / Issue 1/2004
Electronic ISSN: 1476-5926
DOI
https://doi.org/10.1186/1476-5926-3-9

Other articles of this Issue 1/2004

Comparative Hepatology 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine